Cyclin D1 overexpression is the hallmark of mantle cell lymphoma (MCL). However, the importance of cyclin D1 in the maintenance and progression of the disease remains to be defined. The aim of this study was to elucidate the role of cyclin D1 overexpression using an efficient cyclin D1-shRNA and a lentiviral system in well-characterized MCL cell lines. Surprisingly, the knockdown of cyclin D1 led to a moderate retardation in growth, without induction of apoptosis. The cyclin D1-shRNA-transduced MCL cells showed a 15% shift from S phase to G 1 phase of the cell cycle, a weak induction of p27
Introduction
Mantle cell lymphoma (MCL) is a distinct subtype of aggressive B-cell non-Hodgkin's lymphoma with specific pathological features that account for approximately 6% of all lymphomas. The genetic hallmark of MCL is the t(11;14)(q13;q32) chromosomal translocation that juxtaposes the immunoglobulin heavy chain gene (IgH) on 14q32 to the CCND1 gene on 11q13 resulting in the overexpression of cyclin D1. 1 The conventional concept of cyclin D1 oncogenesis postulates that its abnormal expression results in cell cycle deregulation, leading to uncontrolled cell proliferation, probably by overcoming the cell cycle inhibitory effects of Rb and the cyclin-dependent kinase (CDK) inhibitor, p27
Kip1 . [2] [3] [4] [5] [6] In agreement with this hypothesis, it has been shown recently that MCL cases with high cyclin D1 mRNA levels, due to predominant expression of a truncated more stable 1.5 kb isoform, show a higher proliferation rate and shorter survival compared with cases with expression of the conventional 4.5 kb mRNA transcript. 7 Nonetheless, in human lymphoid neoplasias, overexpression of cyclin D1 does not confer a common biological or clinical behavior and its effects seem to be strongly dependent on the transformed cell type and additional genetic alterations. We have shown that the amount of cyclin D1 at the protein and mRNA level does not necessarily correlate with the proliferation rate in MCL 3 and certainly does not correlate in multiple myeloma cases where expression of cyclin D1 even confers a better prognosis. 8, 9 Furthermore, transgenic mice with a cyclin D1 expression in B cells do not develop lymphomas, and the cooperation with other oncogenes such as c-MYC or RAS are needed for malignant transformation. 10, 11 Interestingly, recent studies have demonstrated that MCL is one of the lymphoid neoplasias with the highest number of chromosomal aberrations that may target other genes involved in the progression of this disease. 12, 13 All these studies open the questions of whether cyclin D1 overexpression represents only an initiating event in MCL lymphomagenesis and whether or not it is also important for the maintenance and progression of the disease. To better understand the role of cyclin D1 in the pathogenesis of MCL, we used siRNA technology to knockdown cyclin D1 in wellcharacterized MCL cell lines, as a model system.
Materials and methods

shRNA sequences and plasmid constructs
Seven short hairpin oligonucleotides directed against cyclin D1 were designed. The sense strand of the most efficient cyclin D1-shRNA sequence (CycD1-C) is gatccccCAAACAGATCATCC GCAAAttcaagagaTTTGCGGATGATCTGTTTGtttttggaaa. Uppercase letters indicate 19-nucleotide (nt) cyclin D1 target sequences and lowercase letters indicate hairpin and sequences necessary for the directional cloning into pSuper vector (Oligoengine, Seattle, WA, USA). Single-strand cyclin D1 oligonucleotides were first annealed and then cloned into the BlgII and HindIII sites of expression vectors as described. 14 The fidelity of cloned double-strand DNA was confirmed by EcoRI/HindIII digestion and DNA sequencing. In parallel, a commonly available control shRNA (Dharmacon Research, Chicago, IL, USA/sequence: gatccccGCCGCUUUGUAGGAUA GAGttcaagagaCACUAUCCUACAAAGCGGCtttttggaaa) that lacks complementary sequences in the human genome was cloned into pSuper vector. Cassettes containing the H1 promoter and cyclin D1-shRNA or control sequences were subcloned into the PacI site of the pFUGW vector, kindly provided by David Baltimore. 15 Rapid screening of the cyclin D1-shRNA sequences for their knockdown efficiency was performed with the BLOCK-iT RNAi Target Screening System (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The D2-shRNA sequence used is gatccccTGAATTACCTGGACCGT TTttcaagagaAAACGGTCCAGGTAATTCAtttttggaaa.
Cell lines and lentiviral infection
HEK293T cells were cultured under standard conditions (37 1C in humidified atmosphere, with 5% CO 2 ) in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum. Human MCL cell lines (Granta 519, Jeko-1, JVM-2, Hbl-2, Rec-1, UPN-1, Z-138) and the control cell lines CM (immortalized B lymphocyctes) and SUDHL-1 (ALCL) were grown in RPMI-1640 medium with 10% fetal calf serum. Hightiter lentiviral vector stocks were produced in HEK293T cells by liposomal-mediated transfection of the modified transfer vector FUGW and the packaging vectors D8.9 and pVSV-G. Virus was harvested after 48 h, filtrated and concentrated by ultrafiltration. Titers of virus preparations were determined by measuring the amount of green fluorescence protein (GFP)-positive HEK293T cells after infection with several virus dilutions. Aliquots of virus, plus 8 mg/ml of polybrene, were used to infect exponentially growing cells at a multiplicity of infection (MOI) of 45-90. For transduction, cells together with the virus were centrifuged at 1000 g for 90 min, washed, resuspended in fresh medium and recultivated. The infectivity was determined after 72 h by fluorescence-activated cell sorting analysis of GFP-positive cells.
Real-time quantitative reverse transcription-PCR
Real-time quantitative reverse transcription-PCR analysis was performed as previously described. 16 Gene expression assays from Applied Biosystems (Foster City, CA, USA) were used for the quantification of cyclin D1 and OAS-1 (cyclin D1: Hs00277039_m1; OAS-1: Hs00242943_m1). The sequences for cyclin D2 were 5 0 -CGCAAGCATGCTCAGACCTT-3 0 , 5 0 -TG CGATCATCGACGGTGG-3 0 and 5 0 -FAM-TGCCACCGACTTT AAGTTTGCCATGT-TAMRA-3 0 ; the sequences for cyclin D3 and TATA box-binding protein (TBP) as the housekeeping gene have already been described. 17, 18 Before the experiments started, the linear range of the assays was validated with a dilution curve using transcribed RNA from uninfected cell lines. Data were analyzed using the DC T method as previously described. 16 
Western blotting
Cell line pellets were immersed in tissue protein extraction reagent lysis buffer (Pierce, Rockford, IL, USA) containing one protease inhibitor tablet (Complete Mini; Roche Diagnostics, Mannheim, Germany) and phosphatase inhibitor cocktail 1 and 2 (Sigma, St Louis, MO, USA) and processed as previously described. 16 The following antibodies were used: cyclin D1, cyclin E, CDK2, CDK4 (Santa Cruz Biotechnology, Santa Cruz, CA, USA); cyclin D2, phospho-Rb (Ser807/811) (Cell Signaling Technology, Beverly, MA, USA); cyclin D3, p27 (BD, San Jose, CA, USA); a-tubulin (Sigma).
Proliferation assay
Cell proliferation/viability was determined by the MTS assay (Promega, Madison, WI, USA). The assay was performed in six-well plates, according to the manufacturer's instructions (1 Â 10 5 cells per ml).
Analysis of cell cycle and apoptosis by flow cytometry
Flow cytometric analysis was performed following the protocol described by Nuesse et al. 19 (LSR II flow cytometer; BD). This protocol is suitable for measuring cell cycle distribution and cells in apoptosis (subdiploid cells o2n). Annexin-V-Fluosstaining kit (Roche Diagnostics) was used to stain apoptotic cells. Data were analyzed with the ModFit LT Software version 3.0 (Verity Software, Topsham, ME, USA).
Results
Quantification of cyclins D1, D2 and D3 in MCL cell lines
The level of expression of the different cyclin Ds in MCL cell lines is summarized in Table 1 and Figure 1a . JVM-2 showed the lowest cyclin D1 expression followed by the cell line Hbl-2. In contrast, Granta 519, Jeko-1, Rec-1, Z-138 and UPN-1 showed very high levels of cyclin D1 mRNA. The levels of cyclin D2 showed an inverse correlation with the expression of cyclin D1. JVM-2 and Hbl-2 showed the highest levels of cyclin D2, followed by a lower expression in Granta 519 and Jeko-1 and almost no expression in Rec-1, Z-138 and UPN-1. The level of cyclin D3 was similarly low in the different MCL cell lines. The lymphoblastoid cell line CM, used as control for B cells, expressed predominantly cyclin D2, with low levels of cyclin D3 and no expression of cyclin D1.
Efficient transfer of the cyclin D1-shRNA into the MCL cell lines using a lentiviral vector
The most efficient sequence against cyclin D1, pS-CycD1-C, was cloned into the lentiviral vector pFUGW and the resulting plasmid pF-CycD1 was used to produce viruses in HEK293T cells. In each experiment, three controls were included: (1) a non-manipulated MCL cell line (C); (2) a MCL cell line transduced with an empty virus (pF) and (3) a MCL cell line transduced with a scrambled sequence (pF-C). To find the optimal downregulation of cyclin D1 without off-target effects, the MCL cell lines were transduced with increasing amounts of virus (MOI ¼ 15, 45, 90). MOI of 45 was used for most MCL cell lines in all the following experiments. No interferon response was induced even at an MOI of 90, measured by the expression of the interferon-stimulated gene OAS-1 (data not shown). A great variability of transduction efficiency was found among the different MCL cell lines (Figures 1b and c) . Only low infection rates of 40-50% were obtained for Rec-1 and Hbl-2 even at an MOI of 90, whereas JVM-2 and UPN-1 had moderate infection rates of 75-89%. A high infection rate of almost 100% of the Figure 1b) . A moderate or high infection rate led to a clear reduction of cyclin D1 at the mRNA and protein level (Figure 1c) . Granta 519 showed a downregulation of 82% of cyclin D1 mRNA followed by Z-138 (69%) and UPN-1 (57%). The knockdown of cyclin D1 was stable up to 14 days after infection. It also remained stable after freezing and thawing experiments (data not shown).
Effects of cyclin D1 downregulation on cell growth and apoptosis
To evaluate the effect of cyclin D1 downregulation on cell proliferation, growth curves were generated from treated cells with more than 90% infection rate up to 6 days after infection. A comparison between control and cyclin D1-shRNA-infected cells on day 6 of infection revealed a growth retardation of 32% in Granta 519, 38% in Jeko-1 cells and 49% in Z-138 
Effects of cyclin D1 downregulation on the cell cycle
Owing to the key role of cyclin D1 in the control of the G 1 phase of the cell cycle, the consequences of cyclin D1 knockdown were examined after 7 days of cyclin D1-shRNA infection. Analysis of the cell cycle revealed that Granta 519, Jeko-1 and Z-138 showed a shift of only approximately 15% (range 13-18%) from the S and G 2 phase to the G 1 phase in the cell cycle distribution (Figure 3a ). In addition, the effect of cyclin D1 downregulation on the expression of different G 1 cell cycle components was investigated (Figure 3b ). No changes in the expression of cdk4, cdk2 and cyclin E were observed, whereas the level of p27 Kip1 protein expression was induced. Accordingly, the phosphorylation status of Rb at serine residue 
Upregulation of cyclin D2, but not cyclin D3, after cyclin D1 knockdown
The expression of cyclin D2 and D3 mRNA and protein was investigated in MCL cells treated with the cyclin D1-shRNA virus. Granta 519 showed a 3.7-fold upregulation of cyclin D2 mRNA (Figure 4a ) after 7 days of infection, together with a clear increase in cyclin D2 protein expression, as shown by western blot analysis (Figure 4b ). In contrast, the mRNA and protein levels of cyclin D3 remained unchanged. The upregulation of cyclin D2 was also observed in Jeko-1 (2.5-fold), UPN-1 (3.4-fold) and Z-138 (2.8-fold) (Figure 4c ). JVM-2, which is the only cell line with expression of cyclin D2, showed no upregulation of cyclin D2 or cyclin D3 (Figure 4c ). 
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Downregulation of both cyclins D1 and D2 does not induce cyclin D3 mRNA
To elucidate whether a downregulation of both cyclin D1 and cyclin D2 could intensify the effects observed with the downregulation of cyclin D1 alone, Granta 519 cells were transduced with the combination of a cyclin D1-shRNA and a cyclin D2-shRNA virus (Figures 5a-c) . The double knockdown prevented the induction of cyclin D2 mRNA and protein after cyclin D1 downregulation (Figures 5a and b) , but did not induce the downregulation of cyclin D2 mRNA below the basal levels (Granta 519: 365 vs 129%). Nevertheless, the basal levels of cyclin D2 mRNA are extremely low in MCL cells because of the overexpression of cyclin D1 (Table 1 ; Granta 519 CycD2/TBP: 0.6). No induction of cyclin D3 mRNA and protein was observed (Figures 5a and b) . The effects on cell growth, apoptosis and cell cycle were similar to the effects observed after cyclin D1 downregulation alone (Figure 5c ; data not shown).
Discussion
In this study, we achieved an efficient downregulation of cyclin D1 in MCL cell lines, using a specific cyclin D1-shRNA combined with a lentiviral vector as the delivery system. Surprisingly, the knockdown of cyclin D1 led to only a moderate cell growth retardation of 30-50%, without inducing apoptosis. This was accompanied by a 15% shift from S phase to G 1 phase in the cell cycle distribution, weak induction of p27 Kip1 protein expression, mild reduction in Ser807/811 Rb phosphorylation, and upregulation of cyclin D2 mRNA and protein expression. Our data are in agreement with a previous study, 20 in which cyclin D1 was downregulated in Granta 519, with a different knockdown system, and showed moderate, but distinct inhibition of cell growth without apoptosis.
There are two possible explanations for why only a moderate retardation in cell growth and minor S phase shift was observed. The one logical explanation is that the mild antiproliferative effect of cyclin D1 downregulation is because other cell cycle proteins compensate for the loss of cyclin D1. The increase in cyclin D2 mRNA and protein observed is consistent with this explanation. The three D-type cyclins (cyclins D1, D2 and D3) are encoded by separate genes but exhibit a high degree of amino-acid homology and are expressed in adult tissues in a partially overlapping fashion. 21 Mature B lymphocytes express cyclins D2 and D3, but not cyclin D1 after B-cell receptor crosslinking. Importantly, when cyclin D2 22 or cyclin D3 23 is disrupted in B cells in vitro, the remaining functional D-type cyclins compensate for the loss, indicating that there is a high level of functional redundancy among D-type cyclins. To prove this hypothesis, double knockdown of cyclins D1 and D2 was Cyclin D1 knockdown in MCL M Klier et al performed. Interestingly, prevention of the re-expression of cyclin D2 under cyclin D1-silencing conditions did not cause a further reduction in cell growth and proliferation, suggesting that although the compensatory increase in cyclin D2 may have regulatory significance, it may not be functionally relevant to the survival of the cell. It is worth noting that despite the downregulation of cyclins D1 and D2, no increase in cyclin D3 was observed. These findings are not completely unexpected as it has been shown in mouse models lacking D-type cyclins, or their catalytic partners cdk4 and cdk6, that these proteins are critically required for proliferation only in selected tissues during embryogenesis, implicating the existence of cyclin-independent Cyclin D1 knockdown in MCL M Klier et al mechanisms governing cell proliferation. [24] [25] [26] Therefore, it is possible that cyclin D1, although crucial for the transformation event, as evidenced by the reduced susceptibility to malignant transformation of mice lacking D-type cyclins, 25 is not longer necessary for the maintenance and progression of the disease.
The second possible explanation is that the chromosomal translocation leading to cyclin D1 overexpression is an initiating event in MCL lymphomagenesis, followed by additional genetic events at later stages of the disease, which make cyclin D1 (and D2) dispensable. In support of this hypothesis is the fact that MCL cell lines, in general, mimic aggressive MCL that have frequent aberrations in cell cycle regulatory genes, which represent alternative pathogenetic mechanisms further disrupting the G1/S transition. To investigate whether this genetic heterogeneity influences the response to cyclin D1 knockdown, we studied seven MCL cell lines carrying different secondary genetic deletions and mutations, which lead to the loss of tumor suppressor genes (for example, p16 in Granta 519 and Z-138, p53 in Jeko-1, Rb in UPN-1) or to the amplification of oncogenes (for example, Bcl-2 in Granta 519 and UPN-1). 27 Remarkably, the effect of cyclin D1 downregulation was similar in all the investigated MCL cell lines.
The lack of apoptosis observed, despite efficient cyclin D1 knockdown, supports previous studies that have shown that MCL cells are resistant to apoptosis because of altered apoptotic pathways. [28] [29] [30] These in vitro findings are of practical importance for the treatment of MCL patients. MCL is usually resistant to standard-dose chemotherapeutic reagents, and even with high-dose chemotherapy with or without stem cell transplantation, the prognosis of patients with MCL remains poor. 31 Therefore, the paradigm of cell cycle dysregulation has been used as the starting point for new therapies for MCL, aimed at cyclin D1 synthesis or function, such as mTOR inhibitors, which block mRNA translation of cell cycle proteins including cyclin D1, or inhibitors of CDK such as flavopiridol 32 and others. The reasoning behind these approaches is that if cyclin D1 is the main force inducing proliferation, the inhibition of cyclin D1 directly or indirectly could induce biological changes capable of inhibiting cell growth and/or promoting cell death. Our findings do not support this contention, as strategies inhibiting cyclin D1 functional activity alone might be hampered by the redundancy of the system, resulting in a low probability of treatment response.
In contrast to this assumption, most of the studies using novel drugs targeting crucial biological pathways, which affect cyclin Cyclin D1 knockdown in MCL M Klier et al D1 in MCL only indirectly, for example proteasome inhibitors 33 or histone deacetylase inhibitors, 34, 35 have shown the induction of apoptosis, indicating cyclin D1-independent mechanisms of action. Accordingly, a recent in vitro study revealed that the cytotoxic effect of the proteasome inhibitor Bortezomib (PS-341, Velcade s ) is secondary to the accumulation of pro-apoptotic proteins and not because of the downregulation of cyclin D1 in the treated cells. 36 In conclusion, this study exemplifies a highly efficient system for specific gene knockdown in lymphoid cells. This system enables the direct and specific downregulation of cyclin D1 in MCL cell lines and gives the unique opportunity to investigate the influence of cyclin D1 overexpression in the pathogenesis of MCL. The moderate effects of cyclin D1 knockdown, alone or together with cyclin D2, on survival and proliferation are likely the result of compensatory cyclin-independent mechanisms governing the cell cycle. [24] [25] [26] On the other hand, it can also be taken as support for the hypothesis that the chromosomal translocation leading to cyclin D1 overexpression is only an initiating event in MCL lymphomagenesis and is overruled by secondary genetic events at later stages of the disease.
